370 related articles for article (PubMed ID: 31991614)
1. Prognosis, Biology, and Targeting of
Flynt E; Bisht K; Sridharan V; Ortiz M; Towfic F; Thakurta A
Cells; 2020 Jan; 9(2):. PubMed ID: 31991614
[TBL] [Abstract][Full Text] [Related]
2. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
Thakurta A; Ortiz M; Blecua P; Towfic F; Corre J; Serbina NV; Flynt E; Yu Z; Yang Z; Palumbo A; Dimopoulos MA; Gutierrez NC; Goldschmidt H; Sonneveld P; Avet-Loiseau H
Blood; 2019 Mar; 133(11):1217-1221. PubMed ID: 30692124
[TBL] [Abstract][Full Text] [Related]
3. A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Durand R; Descamps G; Bellanger C; Dousset C; Maïga S; Alberge JB; Derrien J; Cruard J; Minvielle S; Lilli NL; Godon C; Le Bris Y; Tessoulin B; Amiot M; Gomez-Bougie P; Touzeau C; Moreau P; Chiron D; Moreau-Aubry A; Pellat-Deceunynck C
Blood; 2024 Mar; 143(13):1242-1258. PubMed ID: 38096363
[TBL] [Abstract][Full Text] [Related]
4. Hierarchy of mono- and biallelic
Munawar U; Rasche L; Müller N; Vogt C; Da-Via M; Haertle L; Arampatzi P; Dietrich S; Roth M; Garitano-Trojaola A; Steinhardt MJ; Strifler S; Gallardo M; Martinez-Lopez J; Bargou RC; Heckel T; Einsele H; Stühmer T; Kortüm KM; Barrio S
Blood; 2019 Sep; 134(10):836-840. PubMed ID: 31340981
[No Abstract] [Full Text] [Related]
5. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
Lodé L; Eveillard M; Trichet V; Soussi T; Wuillème S; Richebourg S; Magrangeas F; Ifrah N; Campion L; Traullé C; Guilhot F; Caillot D; Marit G; Mathiot C; Facon T; Attal M; Harousseau JL; Moreau P; Minvielle S; Avet-Loiseau H
Haematologica; 2010 Nov; 95(11):1973-6. PubMed ID: 20634494
[TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.
Herrero AB; Rojas EA; Misiewicz-Krzeminska I; Krzeminski P; Gutiérrez NC
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916892
[TBL] [Abstract][Full Text] [Related]
7. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.
Munawar U; Roth M; Barrio S; Wajant H; Siegmund D; Bargou RC; Kortüm KM; Stühmer T
Sci Rep; 2019 Dec; 9(1):18062. PubMed ID: 31792264
[TBL] [Abstract][Full Text] [Related]
8. Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma.
Liu E; Sudha P; Becker N; Jaouadi O; Suvannasankha A; Lee K; Abonour R; Abu Zaid M; Walker BA
Blood Cancer J; 2023 Sep; 13(1):144. PubMed ID: 37696786
[TBL] [Abstract][Full Text] [Related]
9. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.
Martello M; Poletti A; Borsi E; Solli V; Dozza L; Barbato S; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Vigliotta I; Rizzello I; Rocchi S; Armuzzi S; Testoni N; Marzocchi G; Martinelli G; Cavo M; Terragna C
Blood Cancer J; 2022 Jan; 12(1):15. PubMed ID: 35082295
[TBL] [Abstract][Full Text] [Related]
10. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.
Xiong W; Wu X; Starnes S; Johnson SK; Haessler J; Wang S; Chen L; Barlogie B; Shaughnessy JD; Zhan F
Blood; 2008 Nov; 112(10):4235-46. PubMed ID: 18337559
[TBL] [Abstract][Full Text] [Related]
11. Subclonal
Shah V; Johnson DC; Sherborne AL; Ellis S; Aldridge FM; Howard-Reeves J; Begum F; Price A; Kendall J; Chiecchio L; Savola S; Jenner MW; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Davies FE; Houlston RS; Cook G; Cairns DA; Jackson G; Kaiser MF;
Blood; 2018 Dec; 132(23):2465-2469. PubMed ID: 30373884
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma: monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up.
Carlebach M; Amiel A; Gaber E; Radnay J; Manor Y; Fejgin M; Lishner M
Cancer Genet Cytogenet; 2000 Feb; 117(1):57-60. PubMed ID: 10700868
[TBL] [Abstract][Full Text] [Related]
13. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
[TBL] [Abstract][Full Text] [Related]
14. p53 haploinsufficiency and functional abnormalities in multiple myeloma.
Teoh PJ; Chung TH; Sebastian S; Choo SN; Yan J; Ng SB; Fonseca R; Chng WJ
Leukemia; 2014 Oct; 28(10):2066-74. PubMed ID: 24625551
[TBL] [Abstract][Full Text] [Related]
15. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
16. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
Tessoulin B; Moreau-Aubry A; Descamps G; Gomez-Bougie P; Maïga S; Gaignard A; Chiron D; Ménoret E; Le Gouill S; Moreau P; Amiot M; Pellat-Deceunynck C
J Hematol Oncol; 2018 Dec; 11(1):137. PubMed ID: 30545397
[TBL] [Abstract][Full Text] [Related]
17.
Drozdkova DH; Gursky J; Minarik J; Überall I; Kolar Z; Trtkova KS
Anticancer Res; 2020 Sep; 40(9):4979-4987. PubMed ID: 32878786
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.
Chin M; Sive JI; Allen C; Roddie C; Chavda SJ; Smith D; Blombery P; Jones K; Ryland GL; Popat R; Rismani A; D'Sa S; Rabin N; Gale RE; Yong KL
Blood Cancer J; 2017 Sep; 7(9):e610. PubMed ID: 29016571
[No Abstract] [Full Text] [Related]
19. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
Chang H; Yeung J; Qi C; Xu W
Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
[TBL] [Abstract][Full Text] [Related]
20. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]